DOI: 10.2807/1560-7917.es.2024.29.7.2400076 ISSN: 1560-7917
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
Danuta M Skowronski, Yuping Zhan, Samantha E Kaweski, Suzana Sabaiduc, Ayisha Khalid, Romy Olsha, Sara Carazo, James A Dickinson, Richard G Mather, Hugues Charest, Agatha N Jassem, Inès Levade, Maan Hasso, Nathan Zelyas, Ruimin Gao, Nathalie Bastien- Virology
- Public Health, Environmental and Occupational Health
- Epidemiology
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28–85).